Intended for healthcare professionals

How I approach primary hyperhidrosis management

Gina M Kavanagh
An article on managing localised hyperhidrosis appeared in these pages three years ago. In it, Kleyn and Hepburn reviewed the problem of excessive sweating and several ways of treating it. Subsequently, botulinum toxin A – Botox® (Allergan Ltd, UK) – has represented a breakthrough in the treatment of hyperhidrosis. Since its advent I have seen a marked increase in the number of referrals for the management of this problem. I offer here an account of my approach to hyperhidrosis, with updated information on its prevalence and information on how to obtain some useful pharmacological agents.
Dermatology in practice 2005; 13(1): 24–26
To continue reading this article, please sign in or register.

Dermatology in practice was previously supported by Wyeth from 2008 to 2010, by Wyeth and Serono in 2007, by Wyeth and Shire from 2005 to 2006, by Medlock Medical in 2004 and by SSL International from 2001 to 2003.

The data, opinions and statements appearing in the articles herein are those of the contributor(s) concerned; they are not necessarily endorsed by the publisher, Editor or Editorial Board. Accordingly the publisher, Editor and Editorial Board and their respective employees, officers and agents accept no liability for the consequences of any such inaccurate or misleading data, opinion or statement.

The title Dermatology in practice is the property of Hayward Medical Publishing and PMGroup Worldwide Ltd and, together with the content, is bound by copyright. Copyright © 2021 PMGroup Worldwide Ltd. All rights reserved. The information contained on the site may not be reproduced, distributed or published, in whole or in part, in any form without the permission of the publishers. All correspondence should be addressed to:

ISSN 0262-5504 (Print) ISSN 2049-8446 (Online)